<?xml version='1.0' encoding='utf-8'?>
<document id="18841517"><sentence text="Assessing and minimizing time-dependent inhibition of cytochrome P450 3A in drug discovery: a case study with melanocortin-4 receptor agonists." /><sentence text="1-[(2R)-2-([[(1S,2S)-1-amino-1,2,3,4-tetrahydronaphthalen-2-yl]carbonyl]amino)-3-(4-chlorophenyl)propanoyl]-N-(tert-butyl)-4-cyclohexylpiperidine-4-carboxamide (1) is a potent melanocortin-4 receptor agonist that exhibited time-dependent inhibition of cytochrome P450 (P450) 3A in incubations with human liver microsomes"><entity charOffset="0-159" id="DDI-PubMed.18841517.s2.e0" text="1-[(2R)-2-([[(1S,2S)-1-amino-1,2,3,4-tetrahydronaphthalen-2-yl]carbonyl]amino)-3-(4-chlorophenyl)propanoyl]-N-(tert-butyl)-4-cyclohexylpiperidine-4-carboxamide" /></sentence><sentence text=" In incubations fortified with potassium cyanide, a cyano adduct was identified by liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis as a cyanonitrosotetrahydronaphthalenyl derivative"><entity charOffset="31-48" id="DDI-PubMed.18841517.s3.e0" text="potassium cyanide" /><entity charOffset="52-57" id="DDI-PubMed.18841517.s3.e1" text="cyano" /><entity charOffset="155-189" id="DDI-PubMed.18841517.s3.e2" text="cyanonitrosotetrahydronaphthalenyl" /><pair ddi="false" e1="DDI-PubMed.18841517.s3.e0" e2="DDI-PubMed.18841517.s3.e0" /><pair ddi="false" e1="DDI-PubMed.18841517.s3.e0" e2="DDI-PubMed.18841517.s3.e1" /><pair ddi="false" e1="DDI-PubMed.18841517.s3.e0" e2="DDI-PubMed.18841517.s3.e2" /><pair ddi="false" e1="DDI-PubMed.18841517.s3.e1" e2="DDI-PubMed.18841517.s3.e1" /><pair ddi="false" e1="DDI-PubMed.18841517.s3.e1" e2="DDI-PubMed.18841517.s3.e2" /></sentence><sentence text=" The detection of this adduct suggested that a nitroso species was involved in the formation of a metabolite intermediate (MI) complex that led to the observed P450 inactivation"><entity charOffset="47-54" id="DDI-PubMed.18841517.s4.e0" text="nitroso" /></sentence><sentence text=" Further evidence supporting this hypothesis derived from incubations of 1 with recombinant P450 3A4, which exhibited a lambda(max) at approximately 450 nm" /><sentence text=" The species responsible for this absorbance required the presence of beta-nicotinamide adenine dinucleotide phosphate reduced form (NADPH), increased with increasing incubation time and decreased following the addition of potassium ferricyanide to the incubation mixture, suggestive of an MI complex"><entity charOffset="70-118" id="DDI-PubMed.18841517.s6.e0" text="beta-nicotinamide adenine dinucleotide phosphate" /><entity charOffset="223-245" id="DDI-PubMed.18841517.s6.e1" text="potassium ferricyanide" /><pair ddi="false" e1="DDI-PubMed.18841517.s6.e0" e2="DDI-PubMed.18841517.s6.e0" /><pair ddi="false" e1="DDI-PubMed.18841517.s6.e0" e2="DDI-PubMed.18841517.s6.e1" /></sentence><sentence text=" Similar results were obtained with rat liver microsomes and with recombinant P450 3A1" /><sentence text=" When rats were dosed with indinavir as a P450 3A probe substrate, plasma exposure to indinavir increased three-fold following pretreatment with 1, consistent with drug-drug interaction projections based on the k(inact) and K(I) parameters for 1 in rat liver microsomes"><entity charOffset="27-36" id="DDI-PubMed.18841517.s8.e0" text="indinavir" /></sentence><sentence text=" A similar approach was used to predict the magnitude of the corresponding drug-drug interaction potential in humans dosed with a drug metabolized predominantly by P450 3A, and the forecast area under the curve (AUC) increase ranged from four- to ten-fold" /><sentence text=" These data prompted a decision to terminate further evaluation of 1 as a development candidate, and led to the synthesis of the methyl analogue 2"><entity charOffset="129-135" id="DDI-PubMed.18841517.s10.e0" text="methyl" /></sentence><sentence text=" Methyl substitution alpha to the amino group in 2 was designed to reduce the propensity for formation of a nitroso intermediate and, indeed, 2 failed to exhibit time-dependent inhibition of P450 3A in human liver microsomal incubations"><entity charOffset="1-7" id="DDI-PubMed.18841517.s11.e0" text="Methyl" /><entity charOffset="34-39" id="DDI-PubMed.18841517.s11.e1" text="amino" /><pair ddi="false" e1="DDI-PubMed.18841517.s11.e0" e2="DDI-PubMed.18841517.s11.e0" /><pair ddi="false" e1="DDI-PubMed.18841517.s11.e0" e2="DDI-PubMed.18841517.s11.e1" /></sentence><sentence text=" This case study highlights the importance of mechanistic studies in support of drug-discovery and decision-making processes" /><sentence text="" /></document>